REPRINTED ARTICLE
[EDlTOn'S NOTE: The sulfone treatm en t of lepros y has app arently led to g reater success th an a ny othe r th erap y for this disease in its age-long history. Since th e first exte nd ed report on sulfone thera py is not w ide ly access ible to subscribers to the I NTE HNATIONA L JOUHNA L OF LEPHOsY it is he re reprinted for its gell e ra l interest.] Prom in , th e sodium salt of p. p . diaminodiphenylsulfon e n. n. didextrose sulfonate, has been used in experim ental tuberculosis in guin ea pi gs w ith remarkable success (I). Its clini cal tri al in hum an tub erculosis as a chemothera peuti c agent has met with at least promisin g res ults (~) . Its experim ental use in th e treatm ent of leprosy was commenced by the writers over 2 years ago, and at present it is felt th at promin is a therapeuti c agent worthy of further tri al in human leprosy. The writers have had no experience with the dru g in murin e leprosy, but in this type of th e disease th e reports are sugges ti ve of sli ght action (:\).
The Promin Treatment of Leprosy
In our experi ence promin is the bes t of all the sulfonam id e deri vati ves, in cludin g sulfanil amide, sulfathiazole, sulfap yri -d ine, an d sulfadiazin e, which have been used in th e trea tm ent of leprosy at the Nation a l Leprosarium ( .1). It can be regarded as the most encouragin g experimental trcatment ever und ertaken at th e ation al L eprosarium. The writers are not in a position at thi s tim e to state that it possesses any sp ecific action upon Hansen's bacill us. They consider it an advan ce in the ri ght direction in th e chemotheraph y of leprosy and hope that furth er synthes is of th e sulfa chemicals will produce a product whi ch has speci fi c properti es aga inst M. Zeprae and M . tuberculosis.
Our experim ental study was mad e possibl e throu gh the cooperati on of Parke D avis & Co., the manufacturers of promin , which was generously supplied gratis for this experim ent through Dr. E . A. Sharp, the director of the D epartm ent of Clinical In vesti gati on of thi s finn .
TECHNI C
Prom in can be given orall y or intravenously. By oral admini stration it is more toxic, and much larger doses are tolerated hy th e intravenou s route. In OUT preliminary studies promin was given h y mouth to a group of 10 pati ents. Small doses of )~ to 1 gm. wcre tolerated for such short periods that therapeuti c effects seemed unlikely by this method of administration . Severe reactions, particularl y hemolysis, were so easily provoked that this mode of medi cation was soon abandoned. Sin ce then the intravenous injec tion has been favored in all cases. The grea t majority of patients und er trea tm ent have received hom 1 to 5 gm. dail y for 6 days a week, Sunday excepted. Most of th e patients wcre givcn the 5-gm. dose, and the coune of treatment was continuous for months with on ly short intervals of res t of 1 to 2 weeks three tim es a year. In the case reports, in calculatin g the average dail y dose, these res t periods and Sundays are included .
Studics of th e prom in concentration in the blood showed a rapid decline. It was found that on ly traces remain ed 6 to 8 hours followin g the intravenous administration of 5 gm. of promin.
TOXIC MANIFESTATIONS
The intravenous adm inistration of prom in is not free from toxi c reactions. The most important of these is a slow des tru ction of the erythrocytes . This effect is generall y delayed for several weeks, but onc must be constantly on the alert for its development. It is our practice to do complete blood counts routin ely every 2 weeks on every patient on thi s treatment.
In the writers' experience, anemi a occurs · in 46 per cent of cases after 6 weeks of intravenous promin therapy. The longer the continuous coW"se of treatment, the greater the number of anemic patients. It was observed that durin g the compl ete course of trea tment the erythrocytes fell to 3.5 million or less in 71 per cent of cases and in 9 p er cent they fell b elow 3 million. In th e great majority of these Cases an ti anemic therapy, with or without cessations of promin, was successful in raising the red blood cell s and hemoglobin to their former levels.
Satisfactory maintenance of blood levels can b e attained in several ways. A fall of the red blood cells b elow 4 million is an indication to start the patient on inorganic iron, ferrous sulfate, or ferrous carbonate, in adequate doses. This usually restores the red blood cell eount and hemoglobin level, as occurred in 66 per cent of oW" cases. If the erythrocytes continue to decrease, an oral liver and iron preparation is substituted for the iron. This proved adequate in readjusting the erythrocytes and hemoglobin in 60 per cent of cases not responding to iron alone. A certain p erce ntage of patients do not respond to these simple measures. In such instances and when ever the red blood cells decline b elow 3 million, prom in is discontinued temporarily and li ver extract is administered parenterally in additi on to iron orall y. This treatment is continued until the erytmocytes rise above 3.5 million, when it is considered safe to resume promin therapy at the rate of 2 gm. a day, provided the liver and iron are continu ed.
According to Hi ggins (5) promin in guinea pigs exerts a direct toxi c effect on the erythrocytes, leadin g to their destruction and removal from the blood by the spleen. H e found that promin did not p erman entl y damage the bone marrow and regeneration of erythrocytes proceeded dW"-ing continuous administration of the drug.
The writers have observed that in some cases th e institution of promin therapy actually res ulted in an increase in the red blood cell count and the hemoglobin p ercentage. It is b elieved that in such cases the healin g of secondalY infections results in a general improvement in the p ati ent's health, one of the manifestations of which is the lessening of secondary anemia.
Besides a decrease in the red blood cells, leucopenia has been encountered. It occurred in 3 per cent of the cases under treatment. Severe agranulocytosis did not develop, but it was thought b est to discontinu e promin promptly whenever the white blood cells fell below 3,000. In one case promin treatment was abandoned b ecause the response to injections of p en tnucl eotide and liver extract was unsatisfactory.
A routin e bimonthly urinalysis is another precaution ary measure instituted in this experimental study, since other sulfonamides are known to cause renal impairment. SQ far, no evidence of kidney irritation or damage has been demon stra ted b y the routin e minalyses, which are ~uppl e m ente d by occasional renal fLlIl ctioll tf's ts whell f'ver deemed indicated. Toomey and Tokacs (U) were not successful in attempts to produce urinary concretion in monkeys by intravenous injections of promin doses six times as large as those recomm ended for human beings.
After hemolysis, the most important toxic reaction .was the development of an all ergic dermatitis. This gcnera ll y manifes ted itself as a difFuse maculopapular eruption which was accompanied by intense itching. Dermatitis medicamentosa is, of course, a cause for temporarily discontinuing prom in therapy. In the majority of these allergic patients, desensitization is feasible. After the emption has completely disappeared, promin is resumed in minute doses, 0.1 gm., intravenously. By gradually increasing the dose over a p eriod of approxim ately one month, it is possible to arrive at therapeutic doses of 2 gm. daily without further allergic reaction s. In some cases full doses of 5 gm. are eventually reached without a recurrence of dermatitis.
Allergic dermatitis occurred in 16 p er cent of the patients under study. Twothirds of these have b een desensitized at present. In only 3 per cent of cases the procedure proved entirely unsuccessful ; the others are in the process of desensitization.
Another manifestation is allergic rhinitis, which developed in one patient. After several months the sneezing episodes following each injection of promin ceased.
Other untoward reactions, headaches and nausea, are generally mild and ephemeral. Nausea occurred in 35 p er cent of cases. It is transitory in nature and can b e prevented by injectin g the dmg more slowly. Vomiting followed nausea in only 7 p er cent of cases. It also responds to slower injection, up to 1 minute being required to administer 5 gm. of promin intravenously. Several patients complained of headaches, which were never severe.
An increase in erythema of leprous plaques was noted in 3 p er cent of the cases. This accompanied the first few weeks of treatment and gradually subsided. Its cause is unknown. Acute lepra reaction s with fe ver and th e appea ralH.:e of erythema Il oc\osum occurs less freq uelltly with pr,)-Inill thall wit h most prcviuus experimenta l treatm ents or than wit h the routin e chau 1-moogra oil injections. It was th e cause of discontinuing prom in th erapy in only four cases.
An exacerbation of an iridocyclitis occurred in 10 per cent of cases. In all of th em th e patient had experi enccd frequent previous attacks of iridocyclitis. This drug seems temporaril y to in crease the severity of the ocu lar inflammation, 'vvh ich is generally follow ed by improvement. In on ly one patient the exacerbation of iridocyclitis initiated by promin p ersisted longer than 1 month.
A generali zed lymphadenitis was another unusual toxic manifestation which occurred in one patient. Reduction of the dose of prom in to 1 gm. resulted in the subsidence of the glandu lar enlargement.
CLINICAL MATERIAL
No attempt was made to select minimal or moderately advanced cases with favorable prognosis. Thus only a few cases of neural and maculoanestheti c types are included in the study. All patients treated were bacterioscopically positive at onset and many had never had a negative bacteriologic report during the entire previous period of hospitali zation. Man y patients volunteering for treatm ent had far advanced lepromatous and mixed types of leprosy with poor prognosis. The disease in the majority of cases was showing a definite trend toward aggrava ti on before the institution of promin therapy. Several cases were selected because of certain compli cation s wh ich it was thought might be favorably influenced by the promin. Among these important complications were: Leprous keratitis and iridocyclitis, with p ending loss of vision in some cases; leprous rhinitis with ulcerations, repeated epistaxis and partial obstrLlcti on of nares; leproLis laryngitis with threa tening suffocation; chronic leprous ulceration s; and lepromatous lesions and ulcers of the tongu e, palate, gums, and lips, which usually respond poorly to oth er forms of treatment. The effects of prom in in these co mplications of leprosy have, for th e most part, been good.
Paticnts with eye, nose, and throat complications were cxamined before and during the course of treatment in the eye, ear, nose, and throat clinic, and those with oral lesions were examined in like manner in th e dental clinic.
The eye, car, nose, and throat spe<.:ia list 0. F. D. ) reports th at many patients under promin therap y showed a marked improvemcnt in nasal breathing. The initial examination in these patients reveals ulcerations of the nasal mucolls membrane and excessive mucous secretion , which on drying and crusting produces blockage of the nasal passages. There is also a tendency to frequen t epistaxis. After a course of promin it is observed that thc ul cerations, which arc probably du e to secondary infection , heal, th c excess ivc sccretion and crust formation suhside, and nasal hleeding ceases.
Another observation is that prom in seems to benefit eye complications of leprosy. It is notld that patients on promin therapy do not have so many attacks of acute iridocyclitis as formerly. Two patients have shown by slit lamp examination that leprous pun ctate keratitis has disappeared to a considerable extent.
Objective improvemen t in vision has been marked in only one patien t. This patient started with only light perception and projection in one eye, the other being totally blind. Shortly after the institution of promin parenterall y, the acute iridocyclitis and edema of the cornea gradually improved. This continued until on the last exa mination it was found that he had recovered 20/ 100 vision in his good eye.
Many patients with advanced lepromatous and mixed leprosy show evidence of leprous laryngitis. The symptoms are huskiness of voice, vocal weakness, dryn ess of the throat with unproductive cough, and finally attacks of respiratory difficulty. Six patients with advanced leproll s laryngitis were started on prom in intravenously, and all of them improved, especially in th e quality of their voices and the res toration of comfortable respiration . It is felt that two of these patients escaped a proposed emergcncy tracheotomy because of the benefi cial reli ef attributable to promin therapy.
In the dental clinic it was noted that in several patients leprous lesions of lips, tongu e, gums, and hard and soft palate have diminished and in four patients completely' disappeared after prolonged trcatment with promin. Some mucosal ulcerations of the hard and soft p alatc and of the lips have healed under the influence of promin.
CASE REPORTS
A brief summary of the progress of patients havin g taken at leas t 12 months of promin trea tment is given in the following case reports:
Case 869. vV11ite male, 28 yea rs of age, is a moderately advanced lepromatous ( nodul ar ) case of 12 years' duration. There was little previous improvement during 9 years of hospitalization. A total of 2,030 gm. of promin was given intravenously during 26 months. The average daily dose, including res t periods, was 2.6 gm. After 6 months of treatmen t there was a gradual disappearance of discrete nodules of face and torso. At present the patient appears entirely free of leprous lesions. The monthly skin smears became bacteriologically nega tive after 2 years of treatment. An occasional acid-fast bacillus was found in one subsequent skin smear. Photographic confirmation of improvement is evident.
Case 864. A 36-year-old white male with far-advanced lepromatous ( nodular ) leprosy of 12 years' duration had shown no recent advance in the disease prior to promin therapy. H e was given 1,375 gm. intravenously during a period of 26 months. The daily dose averaged 1.7 gm. including res t periods. These rest periods and hematopoi etic drugs were necessary to combat toxic hemol ytic anemia. The erythrocytes varied from 3.02 to 4.67 million during the course of treatment. It was observed that fa cial nodules definitely retrogressed in size and prominence. This improvement started gradua ll y after about a year's treatment and has been progressive. A troublesome nasal obstruction secondary to lep-rous rhinitis has apparently completely cleared up. General imp rovement is shown in the p atient's ability to pl ay b aseba ll this season for the first time in 3 years.
Case 714. A white male, 23 years of age, with far-advanced mixed type of leprosy showed a progress ive aggravation of the di sease durin g the 13 years pri or to treatment with promin . The course of treatment, of 24 months' durati on, has consisted of 1,819 gm., averagin g 2.5 gm. dail y in cludin g rest peri ods. Several chronic ul cers of the legs have healed, as well as a few small ul cers of the face and hands. Nasa l obstru cti on complica tin g a leprous rhinitis has b een reli eved. The p atient has greater energy and stamin a, but there is no definite objective improvement in leprous lesions.
Case 1206. White male, 59 years old, has a far-ad vanced mixed type of leprosy of 9 years' durati on. H e was gettin g worse before the onset of the p resent treatment. A total of 1,814 gm. of p romi n was injected intravenously during a period of 24 months, an average of 2.8 gm. daily including rest periods. There were very extensive chronic ulcerations of the extremities. These have all healed with the exception of two leg ulcers which are small at present. Nasal obstru ction and bleedin g, symptoms of leprous rhinitis, are reli eved. Previous to promin therapy thi s p ati ent was confined to the infirmary because of general weakness and laryngeal leprosy with threatened suffoca tion. An emergency tracheotomy seemed indica ted . H e is now ambul atory with laryngeal condition improved. Improvement in thi s elderly p atient is definite.
Case 661. A wh ite female, 27 years old, "vith moderately advanced lepromatous ( nodular ) leprosy of 15 years' duration was showin g no evidence of improvement at the tim e of onset of the present treatment. Prom in intravenously was given for 19 months, totalin g 1,265 gm. Incl udin g rest peri ods, the average dail y dose was 2.2 gm. D efinite ohjecti ve improvement is noted . Nodules on arm s and legs are small er and flatter. A few nodul es have disap peared, leavin g a hrowni sh pigmentation. lmprovement has b een COll sistent to date.
Case 1229. A colored male, 43 years of age, was under previous routine treatment for 6 years without any definite improvement. The disease is a moderately advanced mixed type of leprosy. Present treatment totals 717 gm. of prom in given during the COlU'se of 18 months fo r an average daily dose of 1.3 gm., countin g the rest periods. Promin was at first administered orally, but toxic reacti ons prevented its continu ation by thi s route. The grea ter part of the dru g was admini stered intravenously. The first bacteriologica ll y nega ti ve skin smear was recorded after 1 year of trea tment. Because the pati ent disliked dail y injections, sulfathiazo le was fin all y substituted for promin . The mani festations of leprosy have gradu all y receded . There has been one skin smear showin g an occasional acid-fast bacillus since the first negati ve report, but subsequent skin smears have again reverted to nega ti ve. It is felt that promin is responsible fo r the definite objecti ve improvement in thi s case.
Case 1366. White male, 38 years of age, has suffered from mixed type of leprosy of a moderately ad vanced stage for 13 years. The di sease had recentl y b ecome worse. The course of intravenous p romin therapy was of 19 months' duration with short intervals of rest. A total of 2,01l gm . was given for an average of 3.5 gm. dail y. This has resulted in a slight decrease in th e size and elevation of th e nodul es of th e face, chest, and arms. There has also supervened a marked in crease in physical cap aci ty fo r work. Improvement is slight in thi s p ati ent.
Case 1294. W hite male, 34 years of age, has had leprosy for 17 years. The disease was moderately advanced and predominantly lepromatous in type and considered stationary before starting treatm ent with promin intravenously. This treatment was administered fo r 17 months, durin g which tim e 1,523 gm. were injected, an average daily dose of 3 gm. There resul ted a healing of leprous ulcers of th e li ps, mouth, and nose. E ight ul cerations of the legs, th e larges t 4 em. in di ameter and 2 mm . in depth, are also compl etely healed at present. L eprou s infiltration of the fa ce has diminished . During a rest period in D ecember 1941 an erysipeloid reaction of th e face developed and during a rest p eriod in September 1942 a severe cystitis developed . Both conditi ons were relieved upon resumption of prom in and have not recurred during the course of treatment. At one time granulocytopenia developed and the number of leukocytes dropped to a low of 3,000 with a polymorph onuclear coun t of 18 p er cent. This condition responded well to th e temporary disco ntinuance of th e dru g and the injection of li ver extract. The neutroph iles have rema ined w ithin norm al limits since th en, in spite of resumption of full doses of p romin. Im provement in this case seems objecti vely defi n ite.
Case 1413. W hite male, 57 years old, h as had leprosy for 7 years. Prior to institution of prom in therapy the disease had an unfavorab le course and reached a moderately ad vanced stage of the mixed type. Promin was given irregul arly because of poor veins. Orall y it was foun d to p roduce too severe toxic reactions. For m any months the patient received it b y dail y intramuscular injections in th e buttock, which he toleJ'ated in spite of the p ain . In all 519 gm. were administered during a period of 17 months, averaging about 1 gm. dail y. Poor veins and p ainful intramuscul ar inj ections were the cause for substituting sulfathiazole orall y for promin . Under th ese treatments, skin infiltrations subsided and large ulcers of the lower extremities healed partiall y. The p atient has fin all y succeeded in obtainin g two successive negati ve bacteriologic skin smears at monthly intervals. The contribution of promin toward th ese nega tive tests, which occurred 5 months after the treatment was ch anged to sulfathiazole, is questionable. For this reason this case is tabulated as stationary in the following table.
Case 1078. White m ale, 41 years of age, has moderately ad vanced lepromatous ( nodular ) leprosy of 9 years' duration. His condition had been stationary for a year previous to onset of promin th erapy. This treatm ent consisted of 1,121 gm. of prom in given intravenously for a p eriod of 16 months. In spite of several interruptions, because of multiple operations for a squamous carcin oma of the nose, the daily dose averaged 2.3 gm. It was observed that numerous nodules of th e abdomen and arms became Rattened or disappea red entirely, leavin g small scars. During a prolonged p eriod of cessa tion of trea tm ent a few new nodules developed on the abdomen. These receded upon resump tion of treatment. The patient at p resent has again been tran sferred to another hospital for furth er plas tic operations on his nose. It is felt th at imp rovement in this case is objecti ve a nd definite, although not continu ous dlll' to . freq uent interrupti ons in trea tment.
Case 953. W hite male, 29 years of age, has had leprosy for ]0 yea rs. The discase progressed unfavorably prior to trea tm ent. It is lepromatous ( nodul ar ) in type and m oderately adva nced. Trea tm ent to the present has comprised th e intravenous injection of 1,578 gm. of promin durin g a 16 months' peri od for an average of 3.2 gm. a day. Objecti ve improvement is manifes ted by subsidence of lepromatolls p laques of the face and a decrease in infiltrati on of th e legs with some new growth of hair. The patient is encouraged over th e results thus far obtain ed. . Case 1032. W hite male, 28 years of age, has had leprosy for 10 years. The disease has grown progressively worse each year. At the start of promin therapy it had reached a fa r-ad vanced stage and was of mixed type. During the course of 16 months of trea tment he was given 1,505 gm. of promin intravenously for an average of 3. 1 gm . a day. The principal reason for starting trea tment in this patient was the seriousness of ocu lar complications, leprous keratitis, and iridocyclitis, which were des troying his sight. Improvement in vision was definite. At the start of treatment the patient had to b e led into th e room for his injections. At present he reads 20/ 200 and Jaeger IV. Nasal discharge and epistaxis due to leprous rhinitis also ceased .
Case 1293. White female, 34 years of age, has had leprosy for 17 years. At th e time that promin therapy was started th e disease was progressing unfavorably. H er case was classed as a moderately ad vanced lepromatous ( nodular ) type. At present she has had 15 months of trea tm ent totaling 335 gm. and averaging onl y 0.7 gm. dail y. The course and dosage were restricted b ecause of allergic dermatitis which neces-sitated desensitiza tion by graduall y in creasing doses commencing at 0.1 gm. intra-,·enously. A tendency to anemia \",hi ch responded on ly fairly well to li ver, ven trex, and inorganic iron also resulted in frequent interruptions in the course of treatment. It is observed th at some pigmented infiltrated lesions of the arms and thighs are subsiding under th e influence of trea tment. This improvement, however, has been gradual and is as yet slight, so th at this case is recorded as still stationary.
Case 1195. White male, 33 years of age, has had leprosy 12 years. The disease has shown no tendency to improve, and was a moderately ad vanced lepromatous ( nodular ) type at the start of the prom in treatment. This therapy, started 14 months ago, amounts to 1,072 gm. , the average daily dose bein g 2.5 gm. The manifes tation of leprosy in this patient is a diffuse infiltration of th e skin of the entire body. Under promin th erapy there has occurred a gradual but not a pronounced fading of th ese lesions. His condition is classed as stationary until and unless more marked improvement is noted.
Case 575. White male, 37 years of age, has had leprosy for 18 years. The disease is a far-a dvanced mixed type with total blindness. A threatened respiratory obstruction from advancin g leprous laryngitis was the reason for startin g prom in therapy in this patient. Intravenous treatm ent so far h as consisted of 1,251 gm. of promin during a 12 months' period, whieh averaged 3.2 gm. a day. The laryngeal condition has improved . A nasal mucosal leprosy which prevented free nasal breathing also responded favorably. Five leprous ulcerations of the extremities have healed. Leprotic skin infiltration has subsided and skin smears h ave become bacteriologicall y negative for the last 3 consecutive months. Improvement has been unmistakable.
Case 1033. Chinese m ale, 25 years of age, has moderately ad vanced lepromatous leprosy of 8 years' duration. At present he h as received 811 gm. of prom in intravenously durin g 13 months, the average daily dose being 2.3 gm. Close examination shows no demonstrable effect of prom in on the leprosy for either better or worse.
Case 576. W hite male, 21 yea rs of age, has suffered from leprosy for 15 yea rs. The disease had become far advanced and ot the mixed type before prom in th erapy was tried . This patient also had severe chronic nephritis. Prom in was administered intravenously in moderate doses for 13 months, averagin g about 1 gm. dail y and totalin g 391 gm, A marked leprous iridocyclitis subsided but th ere was no improvemen t of leprous keratitis noted . Visual acuity did not improve but frequent nocturia was lessened . Nitrogen retention was not materially altered but ch opped 20 points sincc the las t resumption of promin 6 weeks ago. This patient's condition is still seri ous and at present is considered worse th an at th e start of trea tm ent.
Case 689. White male, 49 years of age, who has had leprosy 18 years, was a faradvanced mixed type before starting on promin. During 13 months 1,325 gm. were administered intravenously for an average dail y dose of 3.3 gm., including th e rc.; t periods. Hapidl y failing vision du e to leprous keratitis and iridocyclitis was the reason for trying promin. Iridocyclitis subsided but th e keratitis remained the same. Nasal obstruction due to a leprous rhinitis is greatly relieved. Multiple ulcers of the legs h ave healed under the inHuence of promin. Two periods of 'interrupti on of treatment were necessary for excis ion of a squamous cell carcinoma of lower lip and a subsequent plas tic repair. Improvement in this case is regarded as definite, although most of it may be attributed to clearing up of secondary infections.
Case 1148. White male, 39 years of agc, has had leprosy for 10 years. The disease was becoming worse and was of a moderately ad vanced mixed type at onset of promin th erapy. Course of treatment consisted of 1,126 gm. of prom in intravenously during a period of 12 months, the average dail y dose being 3.1 gm. including days of rest. Leprous laryngitis was th e reason for instituting trea tment in thi s casco This manifested itself by hoarseness and a tendency to aphonia and dyspnoea. These symptoms were favorably influenced by promin. Sclerodenna of lower legs diminished, and ulcers healed. Nodules on the legs b ecame smaller.
Case 1196. W hite male, 29 years of age, w ho has had leprosy 8 yea rs had shown no definite change prev ious to prom in treatment. The disease was moderately adva nced and lepromatous ( nodul ar ) in typ e. H e received a total of 856 gm. of prom in intravenously durin g 12 months, an average dail y dose of 2.3 gm. Improvement is manifes ted in subsidence of skin inflltration and nodul es of ear lobes. Objecti ve improvement is reHected in th e report of the pa tient's Ilrst negati ve skin tes t a fter 11 months on promin th erapy.
Case 918. l~ ilipino m ale, 19 years of age, has had leprosy for 12 years. The disease is mod erately advanced and of m ixed type. At onse t of prom in th erap y prognosis seemed poor, as th e disease was progressin g unfavorably. A total of 889 gm . of promin was admini stered intravenously d\1r-in g 12 months, whi ch is an average dail y dose of 2.4 gm. A decrease . in th e amount of infiltration and nodul ation of the face and body has become evid ent. T here is also a moderate lessenin g of scleroderm a of th e legs. In spite of this improvement, the p ati ent has sufFered several acute lep ra reaction s with erythema nodosum and has lost 5 pounds in weight.
Case 1399. White male, 20 years of age, has had leprosy for 4 yea rs. The di sease is macul oanes theti e in type and of a mod erately advanced stage. Promin th erapy was comm enced ] 2 months ago. At first it was given orall y, but this method of administration had to be discontinued because of a gastrointes tin al disturbance and the development of hemolysis. The greater p art of the 848 gm. of prom in was given intravenously, an average of 2.2 gm. d ail y includ in g res t peri ods. Macul es of th e body have faded to some extent. Nasal obstru cti on was markedly all eviated . In this case in addititon to parenteral therapy a 5-per cent solution of promin was used as a nasal spray. Skin sm ears are showin g a small er number of ac id-fast bacilli, and th e last nasal smear is reported nega ti ve.
The foll owing tabl e is a summ ati on of th e results of intrave nous promin therapy in th e patients w hose case hi stories a re reported here, each of whom has taken at leas t 12 months of trea tmen t.
Not included in th ese case reports or in Table 1 are 46 additi onal patients who have taken a shorter course of promin intravenously. Some of th em are beginning to show signs of improvement, and a few have reverted from a positive to a negati ve b acterioscop y. The duration of trea tment in this more recent group of patients va ries from 2 to 11 months and averages 8 months.
The preliminary results of intravenous promin th erap y in this group are brieHy indicated in T able 2. Also shown in this table are the number of patients in whom b acteriologic tests became negative and those in whom treatm ent was discontinued for one reason or anoth er.
In th ese more recentl y trea ted cases it can be seen th at an attemp't was made to select a more favorable and less ad vanced type of disease.
There were 16 p ati ents altogether in whom treatment was discontinued for various reasons. This number includes a few patients taking less than 2 months' treatment, who are not otherwise included in this report. The reasons for discontinuing treatment were as follows: Refusal of patient to cooperate, 5; repeated acute lepra reactions with erythema nodosum, 4; patients absconding (improved nodul ar cases), 2; ex folia ti ve dermatitis, 1; leucopenia, 1; previous ad vanced nephritis, 1; and increased icteri c index in a patient with previous hepatitis due to sulfanil amide, 1. The foll owin g table gives pertinent data on all cases which reverted from a positive to a negative b acterioscopy under the influence of promin therapy. -.-in contras t to th e small number in whom unfavorable progress was made under promin therapy cannot well be explained on th e basis of spontaneous improvement alone.
To tes t this im press ion a control experiment was unde rtaken with a prominlike drug, Internal Antiseptic 307, which was administered orally in capsules to one group of p atients while a placebo, lactose with a trace of quinine, in similar capsules was given to anoth er group of patients. The placebo was similar in appearance and taste instead of promin, which is too toxic when given b y mouth . Internal Antiseptic 307 is a Parke D avis product and was furni shed gratis b y this firm for thi s experiment.
There was less objection in this institution to the administration of a pl aceb o orall y than b y th e intravenous route, as it would have been more difficult to m anage a control seri es of patients on intravenous inj ections without arousing their suspicion. The group of patients taking th e 1. A. :307 and those of the control grou p were closely matched as to type and stage of the disease. The dosage of th e dru g and of th e placeb o were th e same, varying from 5 to 15 gr. d ail y and averag ing 10 gr. It was necessary to use th ese sm all doses of 1. A. 307 to obviate toxi c reactions, since this drug has cumul ative properties. The patients of b oth groups were handl ed in exactly th e same manner. During the course of trea tment complete blood coun ts and urin alyses were done every 2 weeks on all patients of b oth groups. Antianemic therapy was administered to patients of either group whenever indicated b y the lab oratory findin gs.
After a period of over 8 months it became apparent that there was a difference in the condition of the two groups of patients. While the course of the disease continued unabated in th e control group, it was checked in a considerable percentage of the treated patients. Complications of the disease, such as ulcerations, rhinitis, laryngitis, and iridocyclitis, frequently improved under 1. A. 307 but were unaffected in the control p atients. A comparison of the results after more than 9 months of treatment is given for the two groups in T able 4. In this tabl e under complications are included : chronic ulcerations, leprous rhinitis, leprous laryngitis, and iridocyclitis.
D ata in the a bove table seem to indicate th at improvements in leprosy under prom in and prominlike drugs can not be attributed only to spontaneous rem issions in th e course of the disease. CONCLUSIONS P romin is the sulfonamide dru g whi ch thus far seems to possess to th e grea tes t extent some chemoth erapcutic p roperti es aga inst leprosy.
W hil e no direc:t evid ence of a specific hacterios tatic or bacteriocida l action against M. lepra e has he en demons tra ted , it has been ohserved th at promin appears cap able of inhibiting th e progress of leprosy in a considerable percentage of cases. As ye t no case of lep rosy has become arres ted under its influence.
It is found th at promin can be sa fely administered intravenously fo r prolonged periods, provided th e blood and urin e are examined frequentl y. W hen these precauti ons are taken, toxic mani fes ta tions are relati vely rare and mild. The mos t important of them, hemolysis, if recogni zed early, is usually controll able and not a cause for discontinu ance of treatment.
Further experim ental and clini cal studi es on the trea tment of leprosy with promin must be conducted before more definite conclusions can be drawn as to its therapeutic value.
It is not cl aimed that promin is a specific for leprosy, but in the writers' es tim ation it is an advance in the right direction in th e therap y of this disease.
Promin can b e considered to have opened a new avenue in the chemotherapy of the mycobacterial diseases. It is hoped that furth er synthesis of sulfa compounds may produce a s ubstance which will s ucceed in saving countless lives in this still dark fi eld of m e dicine.
